Hypoparathyroidism Pipeline

Aug 16, 2024

A year after rejecting it, the FDA has now approved Ascendis Pharma’s once-daily injectable YORVIPATH for hypoparathyroidism treatment. Ascendis Pharma’s YORVIPATH (palopegteriparatide), formerly called TransCon PTH, has been approved for the treatment of adults with hypoparathyroidism. This rare condition, charact...

Sep 25, 2019

Hypoparathyroidism is a rare endocrine condition marked by low-calcium and high-phosphate levels as compared to a normally lower or inappropriate level of normal Parathyroid hormone (PTH). Understanding of the Hypoparathyroidism epidemiological data become difficult, considering that the country-specific data i...